|
|
GovernmentDocs 5/4/2008 | 0 (0) | 28 | 0 | 0 | English
Health and Human ServicesMEDWATCHThe FDA Safety Information and Adverse Event Reporting Program A... problems and product use errorsGeneral Instructions3. Sex Female Male orFDA USE ONLYTriage ... more>>
GovernmentDocs 5/5/2008 | 0 (0) | 49 | 1 | 0 | English
DEPARTMENT OF HEALTH & HUMAN SERVICESPublic Health ServiceFood and Drug Administration Rockville, MD 20857NDA 18-662/S046Hoffman-La Roche Inc. Attention: Joanna Wau... ... more>>
FDADocs 5/8/2008 | 0 (0) | 7 | 0 | 0 | English
Cancer Nanotechnology: New Opportunities for Targeted TherapiesFDA Public Meeting October 10, 2006Piotr Grodzinski, Ph.D. Director, Nanotechnology for Cancer Programs Office of Technology and ... more>>
FDADocs 5/5/2008 | 0 (0) | 31 | 0 | 0 | English
FDA/NIH Joint Symposium on Diabetes Targeting Safe and Effective Prevention and Treatment May... Evaluation and Research (CDER), Food and Drug Administration (FDA), U.S. Department of Health and Human ... more>>
FDADocs 5/9/2008 | 0 (0) | 52 | 1 | 0 | English
Evaluation of Biotechnology-Derived Pharmaceuticals (July 1997) (http://www.fda.gov/cder/guidance ... more>>
bnummer 7/28/2008 | 0 (0) | 96 | 0 | 0 | English
This is a publication from the FDA describing foodborne illness risk factors at retail ... more>>
FDADocs 5/9/2008 | 0 (0) | 28 | 0 | 0 | English
???FDA Regulatory Pathway???2nd Annual FDA and the Changing Paradigm for Tissue Regulation... Regulations that apply Examples of jurisdictional recommendations and decisions ??? Questions and ... more>>
FDADocs 5/9/2008 | 0 (0) | 12 | 0 | 0 | English
ERRATA FDA ODAC BRIEFING DOCUMENT SEPTEMBER 13, 2005 MEETING NDA 21473/S-003 TARCEVA PANCREATIC ADENOCARCINOMA General: There may be some confusion in the document regarding which analysis is the ... more>>
FDADocs 5/9/2008 | 0 (0) | 18 | 0 | 0 | English
1. HOME DISTRICT2. REPORTING UNIT SYMBOL3. CENTRAL FILE NO.4. J.D./T.A.5. COUNTY6. DATENWE7. PRODUCT CODENOL8. OPERATION1234567 09001----... ... more>>
FDADocs 5/9/2008 | 0 (0) | 17 | 0 | 0 | English
SAMPLE NO.AFFIDAVIT(Parcel Post/Parcel Service)STATE OF COUNTY OF2358 PuebloColoradoBefore me,Sidney H. Rogers an employee of the Department of Health and Human... ... more>>
FDADocs 5/9/2008 | 0 (0) | 33 | 0 | 0 | English
Session II:Exjade?? Phase 4 requirementsExjade ?? (deferasirox) Tablets for Oral Suspension (accelerated approval Nov. 2, 2005)DEPARTMENT OF HEALTH & HUMAN SERVICESPub... ... more>>
FDADocs 5/9/2008 | 0 (0) | 29 | 0 | 0 | English
Session II:Exjade?? Phase 4 requirementsExjade ?? (deferasirox) Tablets for Oral Suspension (accelerated approval Nov. 2, 2005)DEPARTMENT OF HEALTH & HUMAN SERVICESPub... ... more>>
FDADocs 5/9/2008 | 0 (0) | 35 | 0 | 0 | English
THE CENTER FOR LIFESTYLE DISEASE~b-6 ~7~P.O . Box 1487" Surprise, AZ 85378July 18, 2006FDA Pre Market Notification for "Absolbotani"Submitted By: This Pre Market Notification is being ... more>>
FDADocs 5/9/2008 | 0 (0) | 22 | 0 | 0 | English
FDA UPDATEMelissa Greenwald, M.D. Division of Human Tissues OCTGT, CBER, FDAAATB 31st Annual Meeting 18 September 2007 Boston, MAFDA Update??? ??? ??? ??? ??? Registration and Listing ... more>>
FDADocs 5/8/2008 | 0 (0) | 24 | 0 | 0 | English
Nanotechnology-Enabled Specifically Targeted ViricidesEugene Seymour, MD, MPH Chief Executive Officer Cell: 310-966-1941 eugene@nanoviricides.com Anil R. Diwan, PhD President Cel... ... more>>
| | | |
| results / page 15/25/50 |
Page: 7 of 33
|
...7...
|
|